Loading...
Market
What will be the outcome of Centessa ($CNTA) ORX750 Phase 2 clinical trial results by June 30, 2025?
2
Resolution / Starting Odds
Positive • 25%
Negative • 25%
Mixed • 25%
No Results • 25%
Official press release from Centessa Pharmaceuticals or clinical trial registry
Story
Centessa ($CNTA) Hits Three-Year High on Positive Phase 1 Data for ORX750
Sep 10, 2024, 02:21 PM
Centessa Pharmaceuticals ($CNTA) has announced positive interim Phase 1 clinical data for its novel Orexin Receptor 2 (OX2R) agonist, ORX750. The study involved acutely sleep-deprived healthy volunteers and has shown promising results. This development has propelled Centessa's stock to a three-year high, highlighting a significant $5 billion opportunity in the narcolepsy market. The milestone was celebrated by the Centessa team, including Mario Accardi.
View original story
Similar markets
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
Negative efficacy and safety concerns • 25%
Successful • 33%
Partially Successful • 33%
Unsuccessful • 33%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results published • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Complete Response (CR) • 25%
Partial Response (PR) • 25%
Stable Disease (SD) • 25%
Progressive Disease (PD) • 25%
